BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Townsend MH, Shrestha G, Robison RA, O'Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res 2018;37:163. [PMID: 30031396 DOI: 10.1186/s13046-018-0817-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Honikel MM, Olejniczak SH. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules 2022;12:1303. [DOI: 10.3390/biom12091303] [Reference Citation Analysis]
2 Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, Rader C. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 2022. [PMID: 35859167 DOI: 10.1038/s41388-022-02416-5] [Reference Citation Analysis]
3 Shah B, Gray J, Abraham I, Chang M. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma. J Oncol Pharm Pract 2022;:10781552221107850. [PMID: 35726199 DOI: 10.1177/10781552221107850] [Reference Citation Analysis]
4 Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 2022;41:119. [PMID: 35361234 DOI: 10.1186/s13046-022-02327-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Saad AA. Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life 2022;15:378-433. [DOI: 10.1080/26895293.2022.2049901] [Reference Citation Analysis]
6 Quach ABV, Little SR, Shih SCC. Viral Generation, Packaging, and Transduction on a Digital Microfluidic Platform. Anal Chem 2022;94:4039-47. [PMID: 35192339 DOI: 10.1021/acs.analchem.1c05227] [Reference Citation Analysis]
7 Al-hadlaq SM, Balto HA, Hassan WM, Marraiki NA, El-ansary AK. Biomarkers of non-communicable chronic disease: an update on contemporary methods. PeerJ 2022;10:e12977. [DOI: 10.7717/peerj.12977] [Reference Citation Analysis]
8 Nguyen KV. Potential molecular link between the β-amyloid precursor protein (APP) and hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme in Lesch-Nyhan disease and cancer. AIMS Neurosci 2021;8:548-57. [PMID: 34877405 DOI: 10.3934/Neuroscience.2021030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gutierrez-Guerrero A, Abrey Recalde MJ, Mangeot PE, Costa C, Bernadin O, Périan S, Fusil F, Froment G, Martinez-Turtos A, Krug A, Martin F, Benabdellah K, Ricci EP, Giovannozzi S, Gijsbers R, Ayuso E, Cosset FL, Verhoeyen E. Baboon Envelope Pseudotyped "Nanoblades" Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells. Front Genome Ed 2021;3:604371. [PMID: 34713246 DOI: 10.3389/fgeed.2021.604371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 DePriest BP, Vieira N, Bidgoli A, Paczesny S. An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. Expert Rev Proteomics 2021;18:767-80. [PMID: 34628995 DOI: 10.1080/14789450.2021.1992276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Morales E, Olson M, Iglesias F, Dahiya S, Luetkens T, Atanackovic D. Role of immunotherapy in Ewing sarcoma. J Immunother Cancer 2020;8:e000653. [PMID: 33293354 DOI: 10.1136/jitc-2020-000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
12 Hernández-López A, Téllez-González MA, Mondragón-Terán P, Meneses-Acosta A. Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Front Pharmacol 2021;12:720692. [PMID: 34489708 DOI: 10.3389/fphar.2021.720692] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Zoine JT, Prince C, Story JY, Branella GM, Lytle AM, Fedanov A, Alexander JS, Porter CC, Doering CB, Spencer HT, Chandrakasan S. Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Ther 2021. [PMID: 34385604 DOI: 10.1038/s41434-021-00283-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists. J Am Acad Dermatol 2021:S0190-9622(21)02144-7. [PMID: 34293386 DOI: 10.1016/j.jaad.2021.07.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang YY, Mo LH, Yang G, Liu JQ, Liu ZQ, Yang LT, Ran PX, Liu ZG, Yang PC. Chimeric antigen-guiding extracellular vesicles eliminate antigen-specific Th2 cells in subjects with food allergy. World Allergy Organ J 2021;14:100522. [PMID: 33717398 DOI: 10.1016/j.waojou.2021.100522] [Reference Citation Analysis]
16 Carpenter E, Nelson S, Bednar F, Cho C, Nathan H, Sahai V, di Magliano MP, Frankel TL. Immunotherapy for pancreatic ductal adenocarcinoma. J Surg Oncol 2021;123:751-9. [PMID: 33595893 DOI: 10.1002/jso.26312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Hemasphere 2021;5:e536. [PMID: 33623882 DOI: 10.1097/HS9.0000000000000536] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Baras A, Bocket L, Beauvais D, Hallaert C, Varlet P, Yakoub-Agha I, Hober D, Alidjinou EK. A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel. J Mol Diagn 2021;23:447-54. [PMID: 33385585 DOI: 10.1016/j.jmoldx.2020.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Krishna D, Rittié L, Tran H, Zheng X, Chen-Rogers CE, McGillivray A, Clay T, Ketkar A, Tarnowski J. Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value. Hum Gene Ther 2021;32:433-45. [PMID: 33023309 DOI: 10.1089/hum.2020.212] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Date V, Nair S. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opin Biol Ther 2021;21:145-60. [PMID: 32882159 DOI: 10.1080/14712598.2020.1819978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, Hégo F, Yakoub-Agha I, Labalette M. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom 2021;100:218-24. [PMID: 32841511 DOI: 10.1002/cyto.b.21941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
22 Griffin AC, Topaloglu U, Davis S, Chung AE. From Patient Engagement to Precision Oncology: Leveraging Informatics to Advance Cancer Care. Yearb Med Inform 2020;29:235-42. [PMID: 32823322 DOI: 10.1055/s-0040-1701983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treat Rev 2020;90:102089. [PMID: 32889360 DOI: 10.1016/j.ctrv.2020.102089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
24 Mhaidly R, Verhoeyen E. Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. Cancers (Basel) 2020;12:E1915. [PMID: 32679920 DOI: 10.3390/cancers12071915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
25 Sahlolbei M, Dehghani M, Kheiri Yeghane Azar B, Vafaei S, Roviello G, D'Angelo A, Madjd Z, Kiani J. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. Int Rev Immunol 2020;39:223-32. [PMID: 32546036 DOI: 10.1080/08830185.2020.1776274] [Reference Citation Analysis]
26 Gouvarchin Ghaleh HE, Bolandian M, Dorostkar R, Jafari A, Pour MF. Concise review on optimized methods in production and transduction of lentiviral vectors in order to facilitate immunotherapy and gene therapy. Biomed Pharmacother 2020;128:110276. [PMID: 32502836 DOI: 10.1016/j.biopha.2020.110276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Wang J, Matosevic S. Functional and metabolic targeting of natural killer cells to solid tumors. Cell Oncol 2020;43:577-600. [DOI: 10.1007/s13402-020-00523-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Velazquez EJ, Brindley TD, Shrestha G, Bitter EE, Cress JD, Townsend MH, Berges BK, Robison RA, Weber KS, O'Neill KL. Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells. Cancer Cell Int 2020;20:127. [PMID: 32317865 DOI: 10.1186/s12935-020-01198-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kamies R, Martinez-Jimenez CP. Advances of single-cell genomics and epigenomics in human disease: where are we now? Mamm Genome 2020;31:170-80. [PMID: 32270277 DOI: 10.1007/s00335-020-09834-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Bhargava A, Mishra DK, Tiwari R, Lohiya NK, Goryacheva IY, Mishra PK. Immune cell engineering: opportunities in lung cancer therapeutics. Drug Deliv Transl Res 2020;10:1203-27. [PMID: 32172351 DOI: 10.1007/s13346-020-00719-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Townsend MH, Bennion K, Robison RA, O’neill KL. Paving the way towards universal treatment with allogenic T cells. Immunol Res 2020;68:63-70. [DOI: 10.1007/s12026-020-09119-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
32 Tong Y, Lear TB, Evankovich J, Chen Y, Londino JD, Myerburg MM, Zhang Y, Popescu ID, McDyer JF, McVerry BJ, Lockwood KC, Jurczak MJ, Liu Y, Chen BB. The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity. JCI Insight 2020;5:133652. [PMID: 31990690 DOI: 10.1172/jci.insight.133652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chen SMY, Krinsky AL, Woolaver RA, Wang X, Chen Z, Wang JH. Tumor immune microenvironment in head and neck cancers. Mol Carcinog 2020;59:766-74. [PMID: 32017286 DOI: 10.1002/mc.23162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
34 Bloemberg D, Nguyen T, MacLean S, Zafer A, Gadoury C, Gurnani K, Chattopadhyay A, Ash J, Lippens J, Harcus D, Pagé M, Fortin A, Pon RA, Gilbert R, Marcil A, Weeratna RD, McComb S. A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells. Mol Ther Methods Clin Dev 2020;16:238-54. [PMID: 32083149 DOI: 10.1016/j.omtm.2020.01.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
35 Hardy IR, Schamel WW, Baeuerle PA, Getts DR, Hofmeister R. Implications of T cell receptor biology on the development of new T cell therapies for cancer. Immunotherapy 2020;12:89-103. [PMID: 31902264 DOI: 10.2217/imt-2019-0046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
36 Zhao Z, Xiao X, Saw PE, Wu W, Huang H, Chen J, Nie Y. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 2020;63:180-205. [PMID: 31883066 DOI: 10.1007/s11427-019-9665-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
37 Britten O, Ragusa D, Tosi S, Kamel YM. MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy? Cells 2019;8:E1341. [PMID: 31671855 DOI: 10.3390/cells8111341] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
38 Hingorani DV, Chapelin F, Stares E, Adams SR, Okada H, Ahrens ET. Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection. Magn Reson Med 2020;83:974-87. [PMID: 31631402 DOI: 10.1002/mrm.27988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
39 Deschamps M, Decot V, Giverne C, Pinturaud M, Vaissié A, Parquet N, Olivero S, Anne-Claire M, Bay JO, Yakoub-Agha I, Ferrand C. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2020;107:S85-93. [PMID: 31547937 DOI: 10.1016/j.bulcan.2019.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Frigerio B, Morlino S, Luison E, Seregni E, Lorenzoni A, Satta A, Valdagni R, Bogni A, Chiesa C, Mira M, Canevari S, Alessi A, Figini M. Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. J Exp Clin Cancer Res 2019;38:326. [PMID: 31337429 DOI: 10.1186/s13046-019-1325-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
41 Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Möhler M, Vogel A. Immunotherapy: New Options in Gastrointestinal Cancers? Visc Med 2019;35:47-51. [PMID: 31312650 DOI: 10.1159/000497293] [Reference Citation Analysis]
42 Poorebrahim M, Sadeghi S, Fakhr E, Abazari MF, Poortahmasebi V, Kheirollahi A, Askari H, Rajabzadeh A, Rastegarpanah M, Linē A, Cid-Arregui A. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci 2019;56:393-419. [PMID: 31314617 DOI: 10.1080/10408363.2019.1633512] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
43 Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol 2019;10:1613. [PMID: 31379824 DOI: 10.3389/fimmu.2019.01613] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 13.0] [Reference Citation Analysis]
44 Strohl WR, Naso M. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies (Basel) 2019;8:E41. [PMID: 31544847 DOI: 10.3390/antib8030041] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
45 Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs 2019;11:621-31. [PMID: 30892136 DOI: 10.1080/19420862.2019.1596511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
46 Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res 2019;38:162. [PMID: 30987642 DOI: 10.1186/s13046-019-1153-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 23.0] [Reference Citation Analysis]
47 Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, Welsh J, Calin GA. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer 2019;58:244-53. [PMID: 30578699 DOI: 10.1002/gcc.22725] [Cited by in Crossref: 39] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
48 Cervera-Carrascon V, Havunen R, Hemminki A. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. Expert Opin Biol Ther 2019;19:443-55. [PMID: 30905206 DOI: 10.1080/14712598.2019.1595582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
49 Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, Cardle II, Johnson A, Gustafson J, Parker N, Vetzel M, Xu LC, Wang EZ, Jensen MC, Klein PJ, Low PS, Leamon CP. Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. Front Oncol 2019;9:151. [PMID: 30941303 DOI: 10.3389/fonc.2019.00151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
50 Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res 2019;38:125. [PMID: 30867007 DOI: 10.1186/s13046-019-1123-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
51 Shin H, Na K. In situ vaccination with biocompatibility controllable immuno-sensitizer inducing antitumor immunity. Biomaterials 2019;197:32-40. [PMID: 30639548 DOI: 10.1016/j.biomaterials.2019.01.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]